COCP · Cocrystal Pharma, Inc.
AI read · Neutral
The AI's read
Finishing dosing brings the candidate closer to an efficacy readout, but the report gives no evidence yet that it works. Trial costs also drove research spending higher, so the progress and added costs do not point clearly one way.